Osteoporosis to cost €38.5bn in Europe’s ‘big 5’ by 2025

- Last updated on GMT

Related tags: Osteoporosis, Vitamin d

Osteoporosis to cost €38.5bn in Europe’s ‘big 5’ by 2025
The healthcare costs of rising European osteoporosis rates will reach €38.5bn by 2025 from €30.7bn in 2010, according to a study that reflected on the problem of an increasingly aged population.

The study, published in the Archives of Osteoporosis,​ notes that in 2010 there were 34,000 bone fracture-related deaths in the five biggest EU economies – Germany, the UK, France, Spain and Italy. Sweden was also included.

Half of those fractures were hip fractures and the report estimated that all fractures added up to a loss in quality-adjusted life years (QALY) of about 850,000.

The report highlights pharma and other interventions but notes patients only receive preventative advice about nutrients like calcium and vitamin D that have been backed by the European Food Safety Authority (EFSA) to boost bone health and even reduce the likelihood of falling in the elderly when patients were receiving, bone protective therapy”.

Increasing bone mass density testing is another intervention the report recommends.

It noted that that the healthcare cost exceeds that of for migraine, stroke, multiple sclerosis, and Parkinson’s disease, and registers at about the same level as rheumatoid arthritis.

Fracture rates will rise by 29% to 3.2 trillion in 2025.

“The assessment of best practices in prevention and treatment and the adoption of these across countries

can potentially result in significant reductions in the burden of osteoporosis,”​ the authors wrote.

They continued: In the few health economic analysis that have been published so far the results have shown that osteoporosis management programmes are a cost-effective intervention for the prevention of fractures. More evidence is needed both on the clinical outcomes and the cost-effectiveness of these programmes; however, it is likely that they will become more widely adopted in the future.”

Source:

Archives of Osteoporosis

DOI 10.1007/s11657-011-0060-1

‘Osteoporosis: Burden, health care provision and opportunities in the European Union’

Authors: O Ström, F Borgström, JA Kanis, J Compston, C Cooper, E V McCloskey, B Jönsson.

Related news

Show more

Related products

show more

Clinically Proven Omega-3 formula for Joint Health

Clinically Proven Omega-3 formula for Joint Health

KD Pharma Group | 29-Apr-2019 | Data Sheet

KD Nutra is pleased to announce the completion of a clinical trial for its Move3™ omega-3 joint formulation. The trial has shown that Move3™ has a significant...

MenaQ7® Partners Benefit From K2 Outreach

MenaQ7® Partners Benefit From K2 Outreach

NattoPharma USA, Inc. | 22-Apr-2019 | Case Study

MenaQ7® K2 as MK-7 provides health benefits for all ages. That is a fact clinically proven by NattoPharma and communicated to practitioners and consumers...

Breakthrough in Women's Health

Breakthrough in Women's Health

Biosearch Life | 08-Apr-2019 | Clinical Study

A new study performed on women with polycystic ovary syndrome (PCOS) and fertility problems has been published in Gynecological Endocrinology. Results...

Related suppliers

1 comment

treatment with Soy Isoflavones has positive effects on BMD in osteopenic postmenopausal women.

Posted by Hadar Sutovsky (Msc.)/SOLBAR,

Effects of the Soy Isoflavones on Bone Metabolism in Osteopenic Postmenopausal Women: 389 postmenopausal women with a bone mineral density (BMD) less than 0.795 g/cm2 at the femoral neck were treated At 24 months, BMD had increased in genistein recipients and decreased in placebo recipients.
Genistein statistically significantly decreased urinary excretion of pyridinoline and deoxypyridinoline, increased levels of bone-specific alkaline phosphatase and insulin-like growth factor I, and did not change endometrial thickness compared with placebo.
From: Marini Herbert et al. Ann Internal Medicine 2007;146:839-847

Report abuse

Follow us

Featured Events

View more

Products

View more

Webinars